Clinical antibody testing can support the prioritisation of vaccine resources and could help inform the long-term UK vaccination strategy, writes Peter Harrison
This is paid-for content from our commercial partners. Find out more
Ensuring the effectiveness of covid-19 vaccines will play a key role in promoting public health, including prioritisation of vulnerable populations, and building and promoting public confidence.
Clinical trial data provided to the MHRA has shown the Pfizer, AstraZeneca and Moderna covid-19 vaccines to be safe and effective, delivering a strong immune response over a six-month period.
Sponsored by
With the UK’s national testing strategy now under way, Siemens Healthineers recognises a time of opportunity and advocates the planning of a government-led immunity surveillance programme, to inform both present and long-term vaccine strategies - measuring immune response, monitoring vaccination effectiveness, and safeguarding public health.
Tools such as quantitative antibody testing would form a critical part of this programme, providing key insights into the ongoing immune status of individuals post-vaccination and measuring the long-term effectiveness of the UK vaccination programme.
The SARS-CoV-2 IgG Antibody Test from Siemens Healthineers identifies neutralising spike protein antibodies. The test is able to determine whether a patient’s immune system is producing the right antibodies in the right quantity to stop or prevent covid-19 infection — demonstrating the immune sufficiency of individuals and indicating any requirements for boosters or re-vaccination.
Clinical antibody testing can support the prioritisation of vaccine resources and could contribute to informing the long-term UK vaccination strategy, helping to establish a threshold for protection or immunity and tracking antibody response and longevity of protection.
The SARS-CoV-2 IgG Antibody Test from Siemens Healthineers is available under CE Mark and has proven to measure neutralising antibodies. In addition to antibody, antigen, and molecular SARS-CoV-2 tests, Siemens Healthineers offers a broad diagnostics portfolio to aid in the prognosis, treatment and follow-up of covid-19 patients.
To find out more, click here.
Roundtable: How covid-19 testing is developing and its future
